Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 18,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions: clofarabine (IV formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Dallas, Texas • Tyler, Texas

Conditions: Myelodysplastic Syndromes
Interventions: ASTX727 LD, ASTX727 SD; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Doxil; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Multiple Myeloma
Interventions: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Duarte, California • St Louis, Missouri • Hackensack, New Jersey + 3 more

Conditions: Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions: External beam radiation and Cyberknife radiosurgery boost and capecitabine; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Tumour
Interventions: HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor; Drug
Lead sponsor: Henlix, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fremont, California

Conditions: Metastatic Melanoma
Interventions: Ipilimumab, GM-CSF; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab 200 mg/mL; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Modified Vaccinia Virus Ankara TBC-M; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Interventions: naquotinib, midazolam; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 7 more

Conditions: Healthy Subjects
Interventions: fosamprenavir + ritonavir + methadone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Buffalo, New York

Conditions: Healthy Volunteers
Interventions: BMS747158; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: Veliparib, Gemcitabine, Intensity modulated radiation therapy; Drug · Radiation
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza, Virus Diseases
Interventions: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gaucher Disease
Interventions: OGT 918; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 4 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Adagrasib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Leukemia, Lymphoma
Interventions: fludarabine phosphate, Cyclophosphamide, PBSC, G-CSF, Donor lymphocytes; Drug · Biological
Lead sponsor: Cancer and Leukemia Group B; Network
Eligibility: Up to 69 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 19
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 16 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Lenalidomide, Ibrutinib, Rituximab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Parkinson Disease
Interventions: ANPD001, Custom Device; Biological · Device
Lead sponsor: Aspen Neuroscience; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 6 more

Conditions: Solid Tumor Malignancy
Interventions: Selinexor, Irinotecan; Drug
Lead sponsor: Martin Gutierrez; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Systemic Lupus Erythematosus
Interventions: NKX019, Cyclophosphamide LD; Biological · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Clofarabine in Adult Patients With Advanced Solid Tumors

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Dasatinib in Combination With Revlimid (and Dexamethasone)

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase I Trial of Smallpox Vaccine

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.

A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease

Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1/2a Study of ANPD001 in Parkinson Disease

Selinexor Combination Ph 1 Study

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus